Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.63 |
| ▸ | ROS1 | P08922 | 3/20 | 0.63 |
| ▸ | MET | P08581 | 3/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.63 |
| ▸ | CDC7 | O00311 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.63 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
| ▸ | PAK4 | O96013 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949852 | 0.92 | EGFR (0.73) | EGFRPTK2ALKROS1MET | |
| Hydrochloric Acid SCHEMBL1039414 | 0.91 | EGFR (0.72) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1037690 | 0.82 | EGFR (0.61) | EGFRPTK2ALKROS1MET | |
| SCHEMBL12726532 | 0.82 | EGFR (0.61) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1039377 | 0.82 | PTK2 (0.72) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1034549 | 0.81 | ULK1 (0.73) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1040110 | 0.81 | PTK2 (0.71) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1036277 | 0.81 | PTK2 (0.65) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1039312 | 0.80 | SYK (0.49) | EGFRPTK2ALKROS1MET | |
| SCHEMBL1040134 | 0.78 | PTK2 (0.70) | EGFRPTK2ALKROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | EGFR 2061/4885PTK2 1495/4885ALK 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.